Comprehensive insight on the factors that help determine optimal first-line therapy for a patient presenting with advanced renal cell carcinoma.
Pembrolizumab/Axitinib Improves Survival vs Responses in Advanced RCC
The biomarker analysis in CHECKMATE-426 showed that pembrolizumab plus sunitinib therapy is associated with positive outcomes with angiogenesis in RCC.
Key Advances Across Kidney Cancer Research and Management at KCRS 2025
Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.
Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer
Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.
Unveiling Advances in GU Cancers: Insights from Oncology Decoded
Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.
Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer
A genitourinary oncologist explained that KIM-1 can be used to diagnose, risk-stratify, and detect disease and monitor disease treatment in patients with kidney cancers.
Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy
David A. Braun, MD, PhD, discusses how neoantigen vaccines are redefining RCC treatment, with the potential to activate potent, lasting T-cell activity.